Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258427 · ClinicalTrials.gov registry record · Phase 2
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
A Phase 2 study of Fanconi Anemia, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00258427: Completed Phase 2 study of Fanconi Anemia, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00258427 is a Phase 2 study of Fanconi Anemia that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 14 participants, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00258427, a Phase 2 study of Fanconi Anemia, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients with high risk Fanconi's anemia. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating high risk patients who are undergoing a donor stem cell transplant for Fanconi's anemia.
Primary Outcome
Graft failure is defined as absolute neutrophil count( ANC ) \<5 x 10\^8/L by day 30.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL filgrastim
- DRUG busulfan
- BIOLOGICAL anti-thymocyte globulin
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2002-03-26 |
| Est. Completion | 2020-10-10 |
| Phase | Phase 2 |
What the finished NCT00258427 record still lists
NCT00258427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Fanconi Anemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00258427 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00258427 about?
NCT00258427 is a clinical study titled "Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia". RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients...
What is the current status of trial NCT00258427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2002-03-26. Estimated completion is 2020-10-10.
What conditions does trial NCT00258427 study?
This clinical trial studies the following conditions: Fanconi Anemia.
What interventions are being tested in trial NCT00258427?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258427?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258427 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fanconi Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00258427's enrollment target sits among peer trials
14 14th of 15 higher than 2 of 15 other Fanconi Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fanconi Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RECRUITING · Phase 2
-
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
ACTIVE NOT RECRUITING · Phase 2
-
Eltrombopag for People With Fanconi Anemia
ACTIVE NOT RECRUITING · Phase 2
-
Hematopoietic Stem Cell Transplant for Fanconi Anemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy